Charles Schwab
JSPR icon

Charles Schwab’s Jasper Therapeutics JSPR Stock Holding History

Charles Schwab’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,648
Closed -$115K – 3531
2025
Q1 		$115K Sell
26,648
-5,689
-18% -$37.9K ﹤0.01% 3322
2024
Q4 		$691K Sell
32,337
-70
-0.2% -$1.46K ﹤0.01% 3042
2024
Q3 		$610K Hold
32,407
– – ﹤0.01% 3091
2024
Q2 		$736K Buy
+32,407
New +$777K ﹤0.01% 3038
2024
Q1 		– Sell
-3,690
Closed -$29.1K – 3496
2023
Q4 		$29.1K Hold
3,690
– – ﹤0.01% 3451
2023
Q3 		$25.8K Hold
3,690
– – ﹤0.01% 3484
2023
Q2 		$50.6K Hold
3,690
– – ﹤0.01% 3419
2023
Q1 		$66.8K Buy
+3,690
New +$68.2K ﹤0.01% 3301

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Charles Schwab's JSPR Position: Q2 2025 in Review

Charles Schwab sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 26,648 shares — an estimated $115K sold.

Charles Schwab first reported a position in JSPR in Q1 2023 and held it in 8 quarters. The position peaked at $736K in Q2 2024. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • Charles Schwab reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 26,648 Jasper Therapeutics shares in Q2 2025, an estimated $115K.
  • Charles Schwab first reported a position in Jasper Therapeutics in Q1 2023 and held it in 8 quarters.
  • Charles Schwab's Jasper Therapeutics position peaked at $736K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.